Trailing-twelve-month (TTM) revenue is $12.13 Million with a year-over-year growth of (48.76%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $3,323,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-12 |
| Q4 FY2025Period ended 2025-12-31 | $3,271,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-13 |
| Q1 FY2026Period ended 2026-03-31 | $3,114,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-15 |
| Q2 FY2026Period ended 2026-06-30 | $2,427,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-14 |
| TTM revenue | $12,135,000 |
Current P/S: $34,628,311 market capitalization ÷ $12,135,000 TTM revenue = 2.85x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T15:05:18.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $2.43M.
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 16 comparable quarters.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T15:06:30.196Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|
| Cardiovascular | $5M | $3M | $3M |
| Women's Health | $10M | $12M | $9M |
$12.13M
$12.13 Million
(48.76%)
vs. $23.68M a year ago (TTM)
(22.04%)
5 Year compound annual growth rate
1 Year
(48.76%)
3 Year
(27.04%)
5 Year
(22.04%)
10 Year
N/A
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $12.29M | ($12.08M) | (49.57%) |
| 2024 | $24.38M | ($370,000) | (1.50%) |
| 2023 | $24.75M | +$896,000 | +3.76% |
| 2022 | $23.85M | ($23.54M) | (49.68%) |
| 2021 | $47.39M | +$4.71M | +11.03% |
| 2020 |
TTM Growth
(48.76%)
3-Year CAGR
(27.04%)
5-Year CAGR
(22.04%)
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T15:06:30.196Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
| $42.68M |
| ($219,000) |
| (0.51%) |
| 2019 | $42.90M | +$3.86M | +9.90% |
